Lyell Immunopharma, Inc. (LYEL): 7 insider purchases in the last two years.
| Filed | Insider | Shares | Price | Value | Type |
|---|---|---|---|---|---|
| Mar 9, 2026 | Berns Paul L TenPercentOwner | 488,090 | $25.61 | $12.5M | no history |
| Mar 9, 2026 | ARCH Venture Partners IX Overage, L.P. TenPercentOwner | 488,090 | $25.61 | $12.5M | no history |
| Apr 2, 2025 | Brawley Otis W Director | 35,640 | $0.56 | $20.0K | no history |
| Mar 25, 2025 | Ramachandra Sumant Director | 200,000 | $0.58 | $116.0K | no history |
| Mar 18, 2025 | Seely Lynn Director, Officer | 175,000 | $0.61 | $106.8K | no history |
| Mar 18, 2025 | Newton Charles W. Officer | 200,000 | $0.56 | $112.0K | no history |
| Mar 18, 2025 | Klausner Richard Director | 158,000 | $0.60 | $94.8K | no history |
Open-market purchases from SEC Form 4. "Opportunistic" = this insider trades every year but not on a fixed schedule (Cohen, Malloy & Pomorski); "routine" buys carry little information.
Free account. Know when insiders, famous funds or Congress trade it.